A Phase 1/2 interventional study of mRNA-1010 and Placebo in Seasonal Influenza, sponsored by ModernaTX, Inc.. Completed at 21 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-27.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human — 2 open to participants now, 2 under way, none of them phase 3. mRNA-1010 influenza vaccine · Influenza, Human.
Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, this one is the 5th largest by enrollment, is the only one that started in 2021, is one of 2 in phase 1/2, and was the 1st registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →2 of the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 65+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 9–17 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 4 · Phase 4 1
First in 2021; this study’s year is marked. 1 started in 2021.
This study's enrollment of 885 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 471 across the 12 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 1 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
23 studies in Influenza, Human by Moderna, Inc.: 2 open now, 3 under way, 1 of them phase 3. Of 20 finished, 12 (60%) have results posted.
Among the 23 studies in Influenza, Human by Moderna, Inc., this one is the 12th largest by enrollment, is the only one that started in 2021, is one of 6 in phase 1/2, and was the 3rd registered.
Moderna, Inc.’s Influenza, Human studies by the year they started, since 2015.
1 of the studies testing mRNA-1010 influenza vaccine in Influenza, Human that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07884175ModernaTX, Inc.A Study of Updated mRNA Seasonal Influenza Vaccines | 2026-12-07 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, from their registry updates:
Among Moderna, Inc.’s 23 in Influenza, Human:
This tab as a report to print or save as PDF → With an account.
The study comprises 3 parts: Phase 1/2, Phase 2 Northern Hemisphere (NH), and Phase 2 extension. The primary objective of this study is to evaluate the safety, reactogenicity, and humoral immunogenicity of mRNA-1010 vaccine.
Key Inclusion Criteria:
Phase 1/2:
Phase 2 NH and Phase 2 Extension:
Key Exclusion Criteria:
Phase 1/2:
Phase 2 NH:
Phase 2 Extension:
Other inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive mRNA-1010 at dose level A by intramuscular (IM) injection on Day 1.
Biological: mRNA-1010
Participants will receive mRNA-1010 at dose level B by IM injection on Day 1.
Biological: mRNA-1010
Participants will receive mRNA-1010 at dose level C by IM injection on Day 1.
Biological: mRNA-1010
Participants will receive placebo matching to mRNA-1010 by IM injection on Day 1.
Biological: Placebo
Participants will receive active comparator at dose level A by IM injection on Day 1.
Biological: Active Comparator
Participants will receive mRNA-1010 at dose level D by IM injection on Day 1.
Biological: mRNA-1010
Participants will receive mRNA-1010 at dose level A by IM injection on Day 1.
Biological: mRNA-1010
Participants will receive mRNA-1010 at dose level B by IM injection on Day 1.
Biological: mRNA-1010
Participants will receive active comparator at dose level A by IM injection on Day 1.
Biological: Active Comparator
Participants will receive mRNA-1010 at dose level D by IM injection on Day 1.
Biological: mRNA-1010
Participants will receive mRNA-1010 at dose level E by IM injection on Day 1.
Biological: mRNA-1010
Participants will receive mRNA-1010 at dose level F by IM injection on Day 1.
Biological: mRNA-1010
Sterile liquid for injection
Also known as: Seasonal influenza vaccine
0.9% sodium chloride solution for injection
0.5 milliliter (mL) intramuscular (IM) injection
Also known as: Licensed quadrivalent seasonal influenza
Number of Participants With Solicited Local and Systemic ARs
Solicited ARs (local and systemic) were collected in the electronic diary (eDiary). Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Solicited ARs (local and systemic) considered causally related to injection were graded 0-4; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section and presented by Phase/dose group.
Time frame: 7 days after vaccination
Number of Participants With Unsolicited AEs
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A treatment-emergent AE (TEAE) was defined as any event not present before exposure to vaccine or any event already present that worsens in intensity or frequency after exposure. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsens from baseline and is considered clinically significant in the medical and scientific judgment of the Investigator. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study, regardless of causality, is located in the Reported "Adverse Events" section and presented by each Phase and dose group separately.
Time frame: Up to 28 days after vaccination
Number of Participants With SAEs, AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs)
An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that leads to an unscheduled visit to an healthcare practitioner. This would include visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or COVID-19 and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section and presented by each Phase and dose group separately.
Time frame: Up to 6 months (end of study)
Phase 1/2: Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay for Vaccine-Matched Seasonal Influenza A and B Strains
Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. GMT 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
Time frame: Day 29
Phase 2 NH: GMT of HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains
Humoral immunogenicity relative to that of the active comparator (afluria quadrivalent) was assessed against vaccine-matched Influenza A and B strains at Day 29. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
Time frame: Day 29
Phase 2 Extension: GMT of HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains
Humoral immunogenicity relative to that of the active comparator (afluria quadrivalent) was assessed against vaccine-matched Influenza A and B strains at Day 29. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
Time frame: Day 29
Phase 1/2: Percentage of Participants With Seroconversion, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B
Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion at a participant level was defined as (a) if lower limit of quantification (LLOQ) was 1:10, a post-baseline titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline if baseline was ≥1:10 in anti-HA antibodies; or (b) if LLOQ was \>1:10, a post-baseline titer ≥4 x LLOQ if baseline was \<LLOQ, or 4-fold or greater increase from baseline if baseline was ≥LLOQ in anti-HA antibodies.
Time frame: Day 29
Phase 1/2: Geometric Mean Fold-Rise (GMFR) of Anti-HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% CI was calculated based on the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation.
Time frame: Day 1 (Baseline), Day 29
Phase 2 NH: Percentage of Participants With Seroconversion, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B
Humoral immunogenicity relative to that of the active comparator (afluria quadrivalent) was assessed against vaccine-matched Influenza A and B strains at Day 29. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion at a participant level was defined as (a) if LLOQ was 1:10, a post-baseline titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline if baseline was ≥1:10 in anti-HA antibodies; or (b) if LLOQ was \>1:10, a post-baseline titer ≥4 x LLOQ if baseline was \<LLOQ, or 4-fold or greater increase from baseline if baseline was ≥LLOQ in anti-HA antibodies. 95% CI was calculated using the Clopper-Pearson method
Time frame: Day 29
Phase 2 Extension: Percentage of Participants With Seroconversion, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B
Humoral immunogenicity relative to that of the active comparator (afluria quadrivalent) was assessed against vaccine-matched Influenza A and B strains at Day 29. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion at a participant level was defined as (a) if LLOQ was 1:10, a post-baseline titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline if baseline was ≥1:10 in anti-HA antibodies; or (b) if LLOQ was \>1:10, a post-baseline titer ≥4 x LLOQ if baseline was \<LLOQ, or 4-fold or greater increase from baseline if baseline was ≥LLOQ in anti-HA antibodies. 95% CI was calculated using the Clopper-Pearson method
Time frame: Day 29
Phase 1/2: GMT of Anti-HA Antibodies at Days 1, 8 and 181, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains
Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
Time frame: Day 1 (Baseline), Day 8 and Day 181
Phase 1/2: GMFR of Anti-HA Antibodies at Days 8 and 181, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% CI was calculated based on the difference in the log-transformed values for GMT, then back transformed to the original scale for presentation.
Time frame: Day 1 (Baseline), Day 8 and Day 181
Phase 2 NH and Phase 2 Extension: Percentage of Participants With Seroconversion, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B
Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion at a participant level was defined as (a) if lower limit of quantification (LLOQ) was 1:10, a post-baseline titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline if baseline was ≥1:10 in anti-HA antibodies; or (b) if LLOQ was \>1:10, a post-baseline titer ≥4 x LLOQ if baseline was \<LLOQ, or 4-fold or greater increase from baseline if baseline was ≥LLOQ in anti-HA antibodies.
Time frame: Day 29
Phase 2 NH and Phase 2 Extension: GMFR of Anti-HA Antibodies at Day 29, as Measured by HAI Assay for Vaccine-Matched Seasonal Influenza A and B Strains
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% CI was calculated based on the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation.
Time frame: Day 29
Phase 2 NH and Phase 2 Extension: Percentage of Participants With HAI Titer ≥1:40 at Day 29
Time frame: Day 29
This study was conducted at 20 centers in the United States. The vaccines used in the study were based on the influenza virus strains recommended by the World Health Organization for the southern and northern hemispheres.
| Milestone | Phase 1/2: Placebo | Phase 1/2: mRNA-1010 50 ug | Phase 1/2: mRNA-1010 100 ug | Phase 1/2: mRNA-1010 200 ug | Phase 2 NH: Afluria Quadrivalent 60 ug | Phase 2 NH: mRNA-1010 25 ug | Phase 2 NH: mRNA-1010 50 ug | Phase 2 NH: mRNA-1010 100 ug | Phase 2 Extension: Afluria Quadrivalent 60 ug | Phase 2 Extension: mRNA-1010 6.25 ug | Phase 2 Extension: mRNA-1010 12.5 ug | Phase 2 Extension: mRNA-1010 25 ug |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 45 | 45 | 45 | 45 | 53 | 153 | 149 | 148 | 51 | 50 | 51 | 50 |
| Received at least 1 dose of investigational product | 45 | 45 | 45 | 45 | 53 | 151 | 147 | 147 | 51 | 50 | 50 | 49 |
| Safety analysis set | 45 | 45 | 46 | 44 | 54 | 150 | 147 | 147 | 51 | 50 | 50 | 49 |
| Solicited safety set | 44 | 45 | 46 | 44 | 53 | 149 | 146 | 145 | 51 | 50 | 50 | 49 |
| Per-protocol (pp) set | 41 | 43 | 44 | 41 | 52 | 144 | 138 | 141 | 48 | 49 | 47 | 46 |
| Completed | 40 | 39 | 42 | 38 | 50 | 135 | 133 | 139 | 46 | 47 | 45 | 41 |
| Not completed | 5 | 6 | 3 | 7 | 3 | 18 | 16 | 9 | 5 | 3 | 6 | 9 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 3 | 4 | 2 | 3 | 1 | 10 | 11 | 7 | 4 | 2 | 3 | 8 |
| Withdrew: Withdrawal by subject | 1 | 2 | 1 | 4 | 2 | 8 | 5 | 1 | 1 | 0 | 3 | 1 |
Solicited ARs (local and systemic) were collected in the electronic diary (eDiary). Local ARs included: pain at injection site, erythema (redness) at injection site, swelling/induration (hardness) at injection site, and localized axillary swelling or tenderness ipsilateral to the injection arm. Systemic ARs included: headache, fatigue, myalgia (muscle aches all over the body), arthralgia (aching in several joints), nausea/vomiting, rash, body temperature (potentially fever), and chills. Solicited ARs (local and systemic) considered causally related to injection were graded 0-4; lower score indicates lower severity and a higher score indicates greater severity. Note, not all solicited ARs were considered adverse events (AEs). The Investigator reviewed whether the solicited AR was also to be recorded as an AE. Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is in Reported "Adverse Events" section and presented by Phase/dose group.
| Participants | Placebo | Afluria Quadrivalent 60 ug | mRNA-1010 6.25 ug | mRNA-1010 12.5 ug | mRNA-1010 25 ug | mRNA-1010 50 ug | mRNA-1010 100 ug | mRNA-1010 200 ug | mRNA-1010 >= 50 ug Overall |
|---|---|---|---|---|---|---|---|---|---|
| Grade 1 | 12 | 43 | 22 | 16 | 76 | 65 | 44 | 7 | 116 |
| Grade 2 | 5 | 16 | 17 | 12 | 81 | 70 | 86 | 17 | 173 |
| Grade 3 | 1 | 4 | 4 | 4 | 15 | 31 | 45 | 18 | 94 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A treatment-emergent AE (TEAE) was defined as any event not present before exposure to vaccine or any event already present that worsens in intensity or frequency after exposure. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsens from baseline and is considered clinically significant in the medical and scientific judgment of the Investigator. A summary of SAEs and all nonserious AEs ("Other") reported up to the end of the study, regardless of causality, is located in the Reported "Adverse Events" section and presented by each Phase and dose group separately.
| Participants | Placebo | Afluria Quadrivalent 60 ug | mRNA-1010 6.25 ug | mRNA-1010 12.5 ug | mRNA-1010 25 ug | mRNA-1010 50 ug | mRNA-1010 100 ug | mRNA-1010 200 ug | mRNA-1010 >= 50 ug Overall |
|---|---|---|---|---|---|---|---|---|---|
| All | 6 | 20 | 17 | 14 | 47 | 42 | 46 | 10 | 98 |
| Serious | 1 | 0 | 1 | 0 | 0 | 1 | 2 | 0 | 3 |
| Nonserious | 5 | 20 | 16 | 14 | 47 | 41 | 44 | 10 | 95 |
An SAE was defined as any AE that resulted in death, is life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that leads to an unscheduled visit to an healthcare practitioner. This would include visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or COVID-19 and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the Reported "Adverse Events" section and presented by each Phase and dose group separately.
| Participants | Placebo | Afluria Quadrivalent 60 ug | mRNA-1010 6.25 ug | mRNA-1010 12.5 ug | mRNA-1010 25 ug | mRNA-1010 50 ug | mRNA-1010 100 ug | mRNA-1010 200 ug | mRNA-1010 >= 50 ug |
|---|---|---|---|---|---|---|---|---|---|
| SAE | 2 | 2 | 2 | 0 | 3 | 5 | 4 | 1 | 10 |
| AESI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MAAE | 10 | 27 | 18 | 15 | 58 | 50 | 62 | 12 | 124 |
Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. GMT 95% confidence interval (CI) was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
| Titer | Phase 1/2: Placebo | Phase 1/2: mRNA-1010 50 ug | Phase 1/2: mRNA-1010 100 ug | Phase 1/2: mRNA-1010 200 ug |
|---|---|---|---|---|
| H1N1 | 58.50 (39.17 to 87.38) | 410.71 (262.55 to 642.47) | 331.06 (214.34 to 511.34) | 598.22 (370.14 to 966.84) |
| H3N2 | 56.49 (38.27 to 83.36) | 376.02 (272.52 to 518.81) | 325.07 (234.58 to 450.47) | 537.26 (386.28 to 747.26) |
| Victoria-lineage | 111.14 (75.41 to 163.80) | 237.44 (178.78 to 315.34) | 169.92 (122.03 to 236.60) | 281.00 (213.37 to 370.06) |
| Yamagata-lineage | 103.94 (66.83 to 161.65) | 379.02 (277.02 to 518.57) | 319.07 (218.60 to 465.73) | 456.36 (341.14 to 610.50) |
Humoral immunogenicity relative to that of the active comparator (afluria quadrivalent) was assessed against vaccine-matched Influenza A and B strains at Day 29. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
| titer | Phase 2 NH: Afluria Quadrivalent 60 ug | Phase 2 NH: mRNA-1010 25 ug | Phase 2 NH: mRNA-1010 50 ug | Phase 2 NH: mRNA-1010 100 ug |
|---|---|---|---|---|
| H1N1 | 164.00 (120.18 to 223.81) | 298.88 (247.21 to 361.36) | 422.24 (347.72 to 512.73) | 443.62 (366.58 to 536.85) |
| H3N2 | 85.54 (64.33 to 113.74) | 153.43 (128.99 to 182.50) | 187.08 (156.64 to 223.43) | 215.23 (180.75 to 256.28) |
| Victoria-lineage | 147.47 (119.98 to 181.24) | 100.51 (88.63 to 114.00) | 129.56 (113.92 to 147.36) | 123.17 (108.47 to 139.85) |
| Yamagata-lineage | 193.08 (155.16 to 240.27) | 215.19 (188.30 to 245.92) | 230.66 (201.23 to 264.40) | 231.44 (202.38 to 264.68) |
Humoral immunogenicity relative to that of the active comparator (afluria quadrivalent) was assessed against vaccine-matched Influenza A and B strains at Day 29. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
| Titer | Phase 2 Extension: Afluria Quadrivalent 60 ug | Phase 2 Extension: mRNA-1010 6.25 ug | Phase 2 Extension: mRNA-1010 12.5 ug | Phase 2 Extension: mRNA-1010 25 ug |
|---|---|---|---|---|
| H1N1 | 253.07 (180.86 to 354.12) | 228.02 (163.17 to 318.64) | 316.53 (225.12 to 445.06) | 471.56 (334.39 to 664.99) |
| H3N2 | 114.21 (82.80 to 157.55) | 161.58 (117.46 to 222.27) | 216.32 (156.34 to 299.30) | 301.53 (217.28 to 418.45) |
| Victoria-lineage | 155.07 (121.65 to 197.66) | 55.76 (43.81 to 70.97) | 71.12 (55.51 to 91.11) | 83.46 (65.16 to 106.90) |
| Yamagata-lineage | 193.16 (147.41 to 253.12) | 119.54 (91.34 to 156.45) | 178.43 (135.33 to 235.26) | 144.13 (109.16 to 190.29) |
Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion at a participant level was defined as (a) if lower limit of quantification (LLOQ) was 1:10, a post-baseline titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline if baseline was ≥1:10 in anti-HA antibodies; or (b) if LLOQ was \>1:10, a post-baseline titer ≥4 x LLOQ if baseline was \<LLOQ, or 4-fold or greater increase from baseline if baseline was ≥LLOQ in anti-HA antibodies.
| percentage of participants | Phase 1/2: Placebo | Phase 1/2: mRNA-1010 50 ug | Phase 1/2: mRNA-1010 100 ug | Phase 1/2: mRNA-1010 200 ug |
|---|---|---|---|---|
| H1N1 | 4.9 (0.60 to 16.53) | 67.4 (51.46 to 80.92) | 81.8 (67.29 to 91.81) | 90.2 (76.87 to 97.28) |
| H3N2 | 2.4 (0.06 to 12.86) | 81.4 (66.60 to 91.61) | 75.0 (59.66 to 86.81) | 75.6 (59.70 to 87.64) |
| Victoria-lineage | 2.4 (0.06 to 12.86) | 14.0 (5.30 to 27.93) | 15.9 (6.64 to 30.07) | 25.0 (12.69 to 41.20) |
| Yamagata-lineage | 2.4 (0.06 to 12.86) | 41.9 (27.01 to 57.87) | 50.0 (34.56 to 65.44) | 51.2 (35.13 to 67.12) |
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% CI was calculated based on the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation.
| ratio | Phase 1/2: Placebo | Phase 1/2: mRNA-1010 50 ug | Phase 1/2: mRNA-1010 100 ug | Phase 1/2: mRNA-1010 200 ug |
|---|---|---|---|---|
| H1N1 | 1.08 (0.91 to 1.29) | 7.50 (5.00 to 11.26) | 8.69 (6.03 to 12.50) | 11.05 (7.59 to 16.11) |
| H3N2 | 1.05 (0.80 to 1.39) | 7.16 (5.19 to 9.88) | 6.43 (4.54 to 9.10) | 7.13 (5.12 to 9.93) |
| Victoria-lineage | 0.98 (0.80 to 1.20) | 1.95 (1.61 to 2.37) | 1.86 (1.36 to 2.53) | 2.03 (1.50 to 2.75) |
| Yamagata-lineage | 0.92 (0.81 to 1.05) | 3.04 (2.34 to 3.96) | 3.78 (2.70 to 5.28) | 3.55 (2.47 to 5.11) |
Humoral immunogenicity relative to that of the active comparator (afluria quadrivalent) was assessed against vaccine-matched Influenza A and B strains at Day 29. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion at a participant level was defined as (a) if LLOQ was 1:10, a post-baseline titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline if baseline was ≥1:10 in anti-HA antibodies; or (b) if LLOQ was \>1:10, a post-baseline titer ≥4 x LLOQ if baseline was \<LLOQ, or 4-fold or greater increase from baseline if baseline was ≥LLOQ in anti-HA antibodies. 95% CI was calculated using the Clopper-Pearson method
| percentage of participants | Phase 2 NH: Afluria Quadrivalent 60 ug | Phase 2 NH: mRNA-1010 25 ug | Phase 2 NH: mRNA-1010 50 ug | Phase 2 NH: mRNA-1010 100 ug |
|---|---|---|---|---|
| H1N1 | 59.6 (45.10 to 72.99) | 72.2 (64.15 to 79.36) | 84.8 (77.68 to 90.33) | 85.8 (78.95 to 91.12) |
| H3N2 | 40.4 (27.01 to 54.90) | 66.0 (57.62 to 73.65) | 71.7 (63.45 to 79.07) | 78.7 (71.04 to 85.16) |
| Victoria-lineage | 32.7 (20.33 to 47.11) | 22.9 (16.33 to 30.65) | 33.3 (25.54 to 41.86) | 37.1 (29.13 to 45.71) |
| Yamagata-lineage | 32.7 (20.33 to 47.11) | 41.7 (33.52 to 50.17) | 47.8 (39.26 to 56.49) | 51.8 (43.21 to 60.26) |
Humoral immunogenicity relative to that of the active comparator (afluria quadrivalent) was assessed against vaccine-matched Influenza A and B strains at Day 29. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion at a participant level was defined as (a) if LLOQ was 1:10, a post-baseline titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline if baseline was ≥1:10 in anti-HA antibodies; or (b) if LLOQ was \>1:10, a post-baseline titer ≥4 x LLOQ if baseline was \<LLOQ, or 4-fold or greater increase from baseline if baseline was ≥LLOQ in anti-HA antibodies. 95% CI was calculated using the Clopper-Pearson method
| percentage of participants | Afluria Quadrivalent 60 ug | mRNA-1010 6.25 ug | mRNA-1010 12.5 ug | mRNA-1010 25 ug |
|---|---|---|---|---|
| H1N1 | 50.0 (35.23 to 64.77) | 59.2 (44.21 to 73.00) | 68.1 (52.88 to 80.91) | 73.9 (58.87 to 85.73) |
| H3N2 | 43.8 (29.48 to 58.82) | 44.9 (30.67 to 59.77) | 66.0 (50.69 to 79.14) | 80.4 (66.09 to 90.64) |
| Victoria-lineage | 47.9 (33.29 to 62.81) | 10.2 (3.40 to 22.23) | 21.7 (10.95 to 36.36) | 28.3 (15.99 to 43.46) |
| Yamagata-lineage | 47.9 (33.29 to 62.81) | 24.5 (13.34 to 38.87) | 43.5 (28.93 to 58.89) | 39.1 (25.09 to 54.63) |
Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. GMT 95% CI was calculated based on the t-distribution of the log-transformed values then back transformed to the original scale for presentation.
| titer | Phase 1/2: Placebo | Phase 1/2: mRNA-1010 50 ug | Phase 1/2: mRNA-1010 100 ug | Phase 1/2: mRNA-1010 200 ug |
|---|---|---|---|---|
| Day 1 (Baseline): H1N1 | 54.16 (35.85 to 81.83) | 54.73 (37.76 to 79.31) | 38.12 (28.35 to 51.26) | 54.12 (37.26 to 78.61) |
| Day 8: H1N1 | 42.05 (27.89 to 63.40) | 185.61 (125.31 to 274.92) | 163.84 (101.76 to 263.81) | 319.86 (208.59 to 490.50) |
| Day 181: H1N1 | 67.55 (41.88 to 108.96) | 167.28 (121.35 to 230.59) | 74.14 (52.08 to 105.54) | 159.95 (104.34 to 245.20) |
| Day 1 (Baseline): H3N2 | 53.68 (36.84 to 78.22) | 52.52 (37.35 to 73.85) | 50.59 (37.90 to 67.53) | 75.31 (50.06 to 113.30) |
| Day 8: H3N2 | 51.46 (37.34 to 70.91) | 211.76 (148.46 to 302.04) | 220.95 (155.08 to 314.81) | 345.29 (262.51 to 454.16) |
| Day 181: H3N2 | 67.50 (45.07 to 101.09) | 186.06 (136.00 to 254.55) | 158.74 (116.46 to 216.37) | 235.10 (167.17 to 330.64) |
| Day 1 (Baseline): Victoria-lineage | 113.97 (76.71 to 169.33) | 121.61 (86.46 to 171.06) | 91.41 (64.64 to 129.27) | 137.99 (95.73 to 198.91) |
| Day 8: Victoria-lineage | 34.65 (23.93 to 50.17) | 91.27 (68.41 to 121.78) | 113.14 (81.85 to 156.40) | 122.10 (88.63 to 168.20) |
| Day 181: Victoria-lineage | 37.59 (26.09 to 54.17) | 76.56 (55.37 to 105.87) | 72.27 (53.70 to 97.26) | 70.62 (48.32 to 103.19) |
| Day 1 (Baseline): Yamagata-lineage | 113.13 (70.09 to 182.60) | 124.60 (86.34 to 179.83) | 84.47 (55.85 to 127.75) | 128.43 (81.44 to 202.53) |
| Day 8: Yamagata-lineage | 54.68 (36.21 to 82.59) | 118.85 (90.96 to 155.29) | 116.79 (81.49 to 167.37) | 194.38 (141.31 to 267.38) |
| Day 181: Yamagata-lineage | 55.08 (36.30 to 83.57) | 106.23 (79.98 to 141.08) | 69.87 (52.76 to 92.54) | 112.06 (73.69 to 170.39) |
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% CI was calculated based on the difference in the log-transformed values for GMT, then back transformed to the original scale for presentation.
| ratio | Phase 1/2: Placebo | Phase 1/2: mRNA-1010 50 ug | Phase 1/2: mRNA-1010 100 ug | Phase 1/2: mRNA-1010 200 ug |
|---|---|---|---|---|
| Day 8: H1N1 | 0.78 (0.62 to 0.98) | 3.48 (2.35 to 5.14) | 4.30 (2.76 to 6.69) | 5.91 (3.83 to 9.11) |
| Day 181: H1N1 | 1.21 (0.87 to 1.67) | 2.99 (1.95 to 4.57) | 2.18 (1.51 to 3.14) | 2.92 (2.11 to 4.04) |
| Day 8: H3N2 | 0.96 (0.73 to 1.25) | 4.21 (2.77 to 6.40) | 4.37 (2.73 to 6.99) | 4.58 (2.90 to 7.25) |
| Day 181: H3N2 | 1.27 (0.89 to 1.82) | 3.24 (2.37 to 4.41) | 3.27 (2.28 to 4.70) | 3.09 (2.14 to 4.46) |
| Day 8: Victoria-lineage | 0.30 (0.22 to 0.41) | 0.77 (0.54 to 1.10) | 1.24 (0.86 to 1.77) | 0.85 (0.55 to 1.30) |
| Day 181: Victoria-lineage | 0.34 (0.25 to 0.48) | 0.54 (0.37 to 0.80) | 0.82 (0.59 to 1.15) | 0.48 (0.32 to 0.70) |
| Day 8: Yamagata-lineage | 0.48 (0.37 to 0.63) | 0.98 (0.72 to 1.32) | 1.38 (1.00 to 1.90) | 1.51 (1.05 to 2.17) |
| Day 181: Yamagata-lineage | 0.53 (0.40 to 0.69) | 0.77 (0.56 to 1.07) | 0.96 (0.67 to 1.37) | 0.85 (0.66 to 1.09) |
Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Seroconversion at a participant level was defined as (a) if lower limit of quantification (LLOQ) was 1:10, a post-baseline titer ≥1:40 if baseline was \<1:10 or a 4-fold or greater rise from baseline if baseline was ≥1:10 in anti-HA antibodies; or (b) if LLOQ was \>1:10, a post-baseline titer ≥4 x LLOQ if baseline was \<LLOQ, or 4-fold or greater increase from baseline if baseline was ≥LLOQ in anti-HA antibodies.
| Percentage of participants | Phase 2 NH: Afluria Quadrivalent 60 ug | Phase 2 NH: mRNA-1010 25 ug | Phase 2 NH: mRNA-1010 50 ug | Phase 2 NH: mRNA-1010 100 ug | Phase 2 Extension: Afluria Quadrivalent 60 ug | Phase 2 Extension: mRNA-1010 6.25 ug | Phase 2 NH: mRNA-1010 12.5 ug | Phase 2 Extension: mRNA-1010 25 ug |
|---|---|---|---|---|---|---|---|---|
| H1N1 | 59.6 (45.10 to 72.99) | 72.2 (64.15 to 79.36) | 84.8 (77.68 to 90.33) | 85.8 (78.95 to 91.12) | 50.0 (35.23 to 64.77) | 59.2 (44.21 to 73.00) | 68.1 (52.88 to 80.91) | 73.9 (58.87 to 85.73) |
| H3N2 | 40.4 (27.01 to 54.90) | 66.0 (57.62 to 73.65) | 71.7 (63.45 to 79.07) | 78.7 (71.04 to 85.16) | 43.8 (29.48 to 58.82) | 44.9 (30.67 to 59.77) | 66.0 (50.69 to 79.14) | 80.4 (66.09 to 90.64) |
| Victoria-lineage | 32.7 (20.33 to 47.11) | 22.9 (16.33 to 30.65) | 33.3 (25.54 to 41.86) | 37.1 (29.13 to 45.71) | 47.9 (33.29 to 62.81) | 10.2 (3.40 to 22.23) | 21.7 (10.95 to 36.36) | 28.3 (15.99 to 43.46) |
| Yamagata-lineage | 32.7 (20.33 to 47.11) | 41.7 (33.52 to 50.17) | 47.8 (39.26 to 56.49) | 51.8 (43.21 to 60.26) | 47.9 (33.29 to 62.81) | 24.5 (13.34 to 38.87) | 43.5 (28.93 to 58.89) | 39.1 (25.09 to 54.63) |
The GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. 95% CI was calculated based on the difference in the log-transformed values for GMFR, then back transformed to the original scale for presentation.
| ratio | Phase 2 NH: Afluria Quadrivalent 60 ug | Phase 2 NH: mRNA-1010 25 ug | Phase 2 NH: mRNA-1010 50 ug | Phase 2 NH: mRNA-1010 100 ug | Phase 2 Extension: Afluria Quadrivalent 60 ug | Phase 2 Extension: mRNA-1010 6.25 ug | Phase 2 Extension: mRNA-1010 12.5 ug | Phase 2 Extension: mRNA-1010 25 ug |
|---|---|---|---|---|---|---|---|---|
| H1N1 | 4.19 (2.82 to 6.23) | 7.64 (6.22 to 9.38) | 12.15 (9.38 to 15.73) | 11.96 (9.81 to 14.58) | 6.08 (3.84 to 9.64) | 6.03 (4.22 to 8.61) | 7.21 (4.90 to 10.63) | 12.58 (7.95 to 19.90) |
| H3N2 | 3.17 (2.20 to 4.58) | 6.28 (5.02 to 7.84) | 8.17 (6.63 to 10.06) | 8.70 (7.22 to 10.48) | 3.78 (2.56 to 5.58) | 4.51 (3.15 to 6.46) | 6.66 (4.57 to 9.69) | 9.30 (6.11 to 14.17) |
| Victoria-lineage | 3.30 (2.13 to 5.11) | 2.27 (2.00 to 2.58) | 3.06 (2.60 to 3.60) | 2.79 (2.47 to 3.15) | 3.91 (2.66 to 5.76) | 1.69 (1.30 to 2.20) | 1.84 (1.39 to 2.43) | 2.47 (1.76 to 3.46) |
| Yamagata-lineage | 3.07 (2.19 to 4.29) | 3.33 (2.85 to 3.90) | 3.73 (3.09 to 4.51) | 3.67 (3.15 to 4.27) | 3.72 (2.70 to 5.15) | 2.29 (1.67 to 3.14) | 3.03 (2.18 to 4.21) | 3.08 (2.08 to 4.55) |
| percentage of participants | Phase 2 NH: Afluria Quadrivalent 60 ug | Phase 2 NH: mRNA-1010 25 ug | Phase 2 NH: mRNA-1010 50 ug | Phase 2 NH: mRNA-1010 100 ug | Phase 2 Extension: Afluria Quadrivalent 60 ug | Phase 2 Extension: mRNA-1010 6.25 ug | Phase 2 Extension: mRNA-1010 12.5 ug | Phase 2 Extension: mRNA-1010 25 ug |
|---|---|---|---|---|---|---|---|---|
| H1N1 | 92.3 (81.46 to 97.86) | 97.2 (93.04 to 99.24) | 97.1 (92.74 to 99.20) | 98.6 (94.97 to 99.83) | 95.8 (85.75 to 99.49) | 93.9 (83.13 to 98.72) | 95.7 (85.46 to 99.48) | 97.8 (88.47 to 99.94) |
| H3N2 | 90.4 (78.97 to 96.80) | 91.0 (85.06 to 95.11) | 91.3 (85.30 to 95.43) | 91.5 (85.61 to 95.52) | 81.3 (67.37 to 91.05) | 89.8 (77.77 to 96.60) | 93.6 (82.46 to 98.66) | 97.8 (88.47 to 99.94) |
| Victoria-lineage | 96.2 (86.79 to 99.53) | 91.7 (85.90 to 95.62) | 90.6 (84.43 to 94.89) | 91.4 (85.51 to 95.49) | 100.0 (92.60 to 100.0) | 75.5 (61.13 to 86.66) | 89.1 (76.43 to 96.38) | 82.6 (68.58 to 92.18) |
| Yamagata-lineage | 96.2 (86.79 to 99.51) | 99.3 (96.19 to 99.98) | 96.4 (91.75 to 98.81) | 97.2 (92.90 to 99.22) | 97.9 (88.93 to 99.95) | 93.9 (83.13 to 98.72) | 95.7 (85.16 to 99.47) | 91.3 (79.21 to 97.58) |
Collected over Up to 6 months (Day 181, end of study). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1/2: Placebo | 1/45 (2.2%) | 2/45 (4.4%) | 26/45 (57.8%) |
| Phase 1/2: mRNA-1010 50 ug | 0/45 (0%) | 0/45 (0%) | 39/45 (86.7%) |
| Phase 1/2: mRNA-1010 100 ug | 0/46 (0%) | 0/46 (0%) | 44/46 (95.7%) |
| Phase 1/2: mRNA-1010 200 ug | 0/44 (0%) | 1/44 (2.3%) | 42/44 (95.5%) |
| Phase 2 NH: Afluria Quadrivalent 60 ug | 0/54 (0%) | 1/54 (1.9%) | 37/54 (68.5%) |
| Phase 2 NH: mRNA-1010 25 ug | 0/150 (0%) | 3/150 (2%) | 130/150 (86.7%) |
| Phase 2 NH: mRNA-1010 50 ug | 0/147 (0%) | 5/147 (3.4%) | 133/147 (90.5%) |
| Phase 2 NH: mRNA-1010 100 ug | 1/147 (0.7%) | 4/147 (2.7%) | 133/147 (90.5%) |
| Phase 2 Extension: Afluria Quadrivalent 60 ug | 0/51 (0%) | 1/51 (2%) | 33/51 (64.7%) |
| Phase 2 Extension: mRNA-1010 6.25 ug | 1/50 (2%) | 2/50 (4%) | 45/50 (90%) |
| Phase 2 Extension: mRNA-1010 12.5 ug | 0/50 (0%) | 0/50 (0%) | 38/50 (76%) |
| Phase 2 Extension: mRNA-1010 25 ug | 0/49 (0%) | 0/49 (0%) | 45/49 (91.8%) |
| Event | Phase 1/2: Placebo | Phase 1/2: mRNA-1010 50 ug | Phase 1/2: mRNA-1010 100 ug | Phase 1/2: mRNA-1010 200 ug | Phase 2 NH: Afluria Quadrivalent 60 ug | Phase 2 NH: mRNA-1010 25 ug | Phase 2 NH: mRNA-1010 50 ug | Phase 2 NH: mRNA-1010 100 ug | Phase 2 Extension: Afluria Quadrivalent 60 ug | Phase 2 Extension: mRNA-1010 6.25 ug | Phase 2 Extension: mRNA-1010 12.5 ug | Phase 2 Extension: mRNA-1010 25 ug |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Post-traumatic amnestic disorderPsychiatric disorders | 0/45 | 0/45 | 0/46 | 1/44 | 0/54 | 0/150 | 0/147 | 0/147 | 0/51 | 0/50 | 0/50 | 0/49 |
| Distributive shockVascular disorders | 0/45 | 0/45 | 0/46 | 1/44 | 0/54 | 0/150 | 0/147 | 0/147 | 0/51 | 0/50 | 0/50 | 0/49 |
| Pelvic fractureInjury, poisoning and procedural complications | 0/45 | 0/45 | 0/46 | 1/44 | 0/54 | 0/150 | 0/147 | 0/147 | 0/51 | 0/50 | 0/50 | 0/49 |
| ConcussionInjury, poisoning and procedural complications | 0/45 | 0/45 | 0/46 | 1/44 | 0/54 | 0/150 | 0/147 | 0/147 | 0/51 | 0/50 | 0/50 | 0/49 |
| Kidney contusionInjury, poisoning and procedural complications | 0/45 | 0/45 | 0/46 | 1/44 | 0/54 | 0/150 | 0/147 | 0/147 | 0/51 | 0/50 | 0/50 | 0/49 |
| Lumbar vertebral fractureInjury, poisoning and procedural complications | 0/45 | 0/45 | 0/46 | 1/44 | 0/54 | 0/150 | 0/147 | 0/147 | 0/51 | 0/50 | 0/50 | 0/49 |
| Rib fractureInjury, poisoning and procedural complications | 0/45 | 0/45 | 0/46 | 1/44 | 0/54 | 0/150 | 0/147 | 0/147 | 0/51 | 0/50 | 0/50 | 0/49 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/45 | 0/45 | 0/46 | 1/44 | 0/54 | 0/150 | 0/147 | 0/147 | 0/51 | 1/50 | 0/50 | 0/49 |
| Spinal compression fractureInjury, poisoning and procedural complications | 0/45 | 0/45 | 0/46 | 1/44 | 0/54 | 0/150 | 0/147 | 0/147 | 0/51 | 0/50 | 0/50 | 0/49 |
| Traumatic liver injuryInjury, poisoning and procedural complications | 0/45 | 0/45 | 0/46 | 1/44 | 0/54 | 0/150 | 0/147 | 0/147 | 0/51 | 0/50 | 0/50 | 0/49 |
| Event | Phase 1/2: Placebo | Phase 1/2: mRNA-1010 50 ug | Phase 1/2: mRNA-1010 100 ug | Phase 1/2: mRNA-1010 200 ug | Phase 2 NH: Afluria Quadrivalent 60 ug | Phase 2 NH: mRNA-1010 25 ug | Phase 2 NH: mRNA-1010 50 ug | Phase 2 NH: mRNA-1010 100 ug | Phase 2 Extension: Afluria Quadrivalent 60 ug | Phase 2 Extension: mRNA-1010 6.25 ug | Phase 2 Extension: mRNA-1010 12.5 ug | Phase 2 Extension: mRNA-1010 25 ug |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 7/45 | 33/45 | 40/46 | 40/44 | 17/54 | 110/150 | 120/147 | 122/147 | 25/51 | 37/50 | 32/50 | 41/49 |
| FatigueGeneral disorders | 10/45 | 24/45 | 40/46 | 35/44 | 16/54 | 79/150 | 86/147 | 96/147 | 16/51 | 23/50 | 20/50 | 27/49 |
| MyalgiaMusculoskeletal and connective tissue disorders | 7/45 | 18/45 | 36/46 | 31/44 | 12/54 | 72/150 | 88/147 | 98/147 | 14/51 | 16/50 | 16/50 | 28/49 |
| HeadacheNervous system disorders | 8/45 | 19/45 | 29/46 | 33/44 | 10/54 | 78/150 | 79/147 | 82/147 | 20/51 | 21/50 | 18/50 | 24/49 |
| ChillsGeneral disorders | 2/45 | 14/45 | 26/46 | 31/44 | 6/54 | 44/150 | 52/147 | 73/147 | 8/51 | 9/50 | 5/50 | 18/49 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/45 | 10/45 | 28/46 | 27/44 | 11/54 | 57/150 | 68/147 | 73/147 | 10/51 | 12/50 | 13/50 | 25/49 |
| Injection site lymphadenopathyGeneral disorders | 3/45 | 11/45 | 16/46 | 22/44 | 10/54 | 40/150 | 45/147 | 52/147 | 7/51 | 13/50 | 14/50 | 16/49 |
| VomitingGastrointestinal disorders | 1/45 | 8/45 | 18/46 | 17/44 | 5/54 | 23/150 | 31/147 | 30/147 | 3/51 | 4/50 | 6/50 | 11/49 |
| PyrexiaGeneral disorders | 0/45 | 2/45 | 11/46 | 13/44 | 2/54 | 10/150 | 14/147 | 25/147 | 0/51 | 0/50 | 2/50 | 3/49 |
| COVID-19Infections and infestations | 0/45 | 2/45 | 2/46 | 3/44 | 8/54 | 17/150 | 19/147 | 21/147 | 1/51 | 5/50 | 3/50 | 3/49 |
Safety Set: All randomly assigned participants who received the investigational product.
| Age, Continuous(years) | Phase 1/2: Placebo | Phase 1/2: mRNA-1010 50 ug | Phase 1/2: mRNA-1010 100 ug | Phase 1/2: mRNA-1010 200 ug | Phase 2 NH: Afluria Quadrivalent 60 ug | Phase 2 NH: mRNA-1010 25 ug | Phase 2 NH: mRNA-1010 50 ug | Phase 2 NH: mRNA-1010 100 ug | Phase 2 Extension: Afluria Quadrivalent 60 ug | Phase 2 Extension: mRNA-1010 6.25 ug | Phase 2 Extension: mRNA-1010 12.5 ug | Phase 2 Extension: mRNA-1010 25 ug | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 52.0 (18 to 90) | 48.2 (18 to 74) | 52.2 (19 to 83) | 48.9 (19 to 89) | 52.4 (20 to 86) | 50.4 (18 to 86) | 50.3 (19 to 81) | 49.9 (18 to 82) | 40.8 (19 to 65) | 40.4 (18 to 75) | 42.8 (19 to 76) | 38.9 (21 to 74) | 47.3 (18 to 90) |
| Sex: Female, Male(Participants) | Phase 1/2: Placebo | Phase 1/2: mRNA-1010 50 ug | Phase 1/2: mRNA-1010 100 ug | Phase 1/2: mRNA-1010 200 ug | Phase 2 NH: Afluria Quadrivalent 60 ug | Phase 2 NH: mRNA-1010 25 ug | Phase 2 NH: mRNA-1010 50 ug | Phase 2 NH: mRNA-1010 100 ug | Phase 2 Extension: Afluria Quadrivalent 60 ug | Phase 2 Extension: mRNA-1010 6.25 ug | Phase 2 Extension: mRNA-1010 12.5 ug | Phase 2 Extension: mRNA-1010 25 ug | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 23 | 19 | 25 | 33 | 30 | 89 | 80 | 86 | 24 | 34 | 27 | 30 | 500 |
| Male | 22 | 26 | 21 | 11 | 24 | 61 | 67 | 61 | 27 | 16 | 23 | 19 | 378 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1/2: Placebo | Phase 1/2: mRNA-1010 50 ug | Phase 1/2: mRNA-1010 100 ug | Phase 1/2: mRNA-1010 200 ug | Phase 2 NH: Afluria Quadrivalent 60 ug | Phase 2 NH: mRNA-1010 25 ug | Phase 2 NH: mRNA-1010 50 ug | Phase 2 NH: mRNA-1010 100 ug | Phase 2 Extension: Afluria Quadrivalent 60 ug | Phase 2 Extension: mRNA-1010 6.25 ug | Phase 2 Extension: mRNA-1010 12.5 ug | Phase 2 Extension: mRNA-1010 25 ug | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 12 | 9 | 8 | 12 | 27 | 32 | 29 | 17 | 12 | 14 | 11 | 188 |
| Not Hispanic or Latino | 39 | 33 | 37 | 35 | 42 | 122 | 114 | 114 | 34 | 36 | 35 | 36 | 677 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 4 | 0 | 2 | 1 | 2 | 13 |
| Race/Ethnicity, Customized(Participants) | Phase 1/2: Placebo | Phase 1/2: mRNA-1010 50 ug | Phase 1/2: mRNA-1010 100 ug | Phase 1/2: mRNA-1010 200 ug | Phase 2 NH: Afluria Quadrivalent 60 ug | Phase 2 NH: mRNA-1010 25 ug | Phase 2 NH: mRNA-1010 50 ug | Phase 2 NH: mRNA-1010 100 ug | Phase 2 Extension: Afluria Quadrivalent 60 ug | Phase 2 Extension: mRNA-1010 6.25 ug | Phase 2 Extension: mRNA-1010 12.5 ug | Phase 2 Extension: mRNA-1010 25 ug | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| White | 38 | 38 | 41 | 32 | 45 | 124 | 120 | 124 | 47 | 44 | 39 | 41 | 733 |
| Black or African American | 5 | 5 | 2 | 10 | 6 | 17 | 18 | 18 | 4 | 4 | 8 | 4 | 101 |
| Asian | 1 | 1 | 1 | 0 | 0 | 2 | 3 | 2 | 0 | 0 | 2 | 0 | 12 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 0 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Multiple Race | 0 | 1 | 0 | 0 | 2 | 3 | 1 | 1 | 0 | 1 | 1 | 1 | 11 |
| Other Race | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 4 |
| Race Not Reported | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 2 | 0 | 0 | 0 | 1 | 10 |
| Race Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2021 to primary completion in Sep 2022, 14 months.
Results were first posted in Oct 2023, 1 year 1 month after primary completion.
Of 41 industry-sponsored phase 1/2 interventional studies under Influenza, Human, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 14 months is close to that.
Counting every sponsor, half of 43 studies reached it within 12 months; a quarter within 7 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: mRNA-1010 influenza vaccine